International Stem Cell CORP (ISCO) Form 10-Q — Aug 13, 2026
International Stem Cell Corporation filed its Q2 2026 10-Q showing product sales of $2.675 million, up 9% year over year, but a net loss of $71 thousand versus net income of $129 thousand in the year-ago quarter. Six-month sales rose 9% to $4.99 million while the net loss widened to $291 thousand from $127 thousand. The company again disclosed substantial doubt about its ability to continue as a going concern, holding just $1.1 million of cash against an accumulated deficit of $111.4 million and a stockholders' deficit of $4.2 million. Management stated it does not have sufficient cash to sustain operations for twelve months without additional financing or an extension of existing financing.
Key figures
- Revenue
- 4990000
- Total Debt
- 3256000
- Revenue Yoy
- +9%
- Total Assets
- 5056000
- Cash Position
- 1089000
- Shares Outstanding
- 8004389
- Lct sale price usd
- 25000000
- Q2 2026 revenue usd
- 2675000
- Accumulated deficit usd
- 111394000
- Q2 2026 revenue yoy pct
- +9%
- Intangible impairment usd
- 111000
- Related party note maturity
- September 15, 2026
- Top customer pct of q2 sales
- 61%
- Operating cash flow six months usd
- 288000
- Top customer pct of accounts receivable
- 64%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.